Search Within

Lorenzo Falchi

Formats
  1. Meeting Abstract (96)
  2. Journal Article (23)
  3. Research Letter (6)
  4. Review (5)
  5. Correspondence (2)
  6. Editorial (1)
  7. Guidelines (1)
Groups
  1. Department of Medicine (134)
  2. Hematologic Malignancies, Division of (134)
  3. Center for Hematologic Malignancies (88)
  4. Lymphoma (78)
  5. Sloan Kettering Institute Postdocs (57)
  6. Survivorship Research (54)

More Groups

People
  1. Gilles Salles (66)
  2. Andrew Zelenetz (64)
  3. Maria Palomba (63)
  4. Anita Kumar (61)
  5. Ariela Noy (57)
  6. Alison Moskowitz (54)

More People

Years
  1. 2025 (8)
  2. 2024 (40)
  3. 2023 (43)
  4. 2022 (23)
  5. 2021 (14)
  6. 2020 (6)
Publications
  1. Blood (67)
  2. Journal of Clinical Oncology (11)
  3. Hematological Oncology (9)
  4. Blood Advances (5)
  5. Clinical Lymphoma, Myeloma and Leukemia (5)
  6. Leukemia and Lymphoma (5)

More Publications

Publishers
  1. American Society of Hematology (72)
  2. American Society of Clinical Oncology (11)
  3. Wiley Blackwell (9)
  4. Elsevier Inc. (8)
  5. Taylor & Francis Group (5)
  6. Ferrata Storti Foundation (4)

More Publishers

Results (134)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Relapse is uncommon in patients with large B-cell lymphoma who are in complete remission at the end of fixed-course glofitamab treatment
    Meeting Abstract

    Hutchings, M.; Carlo-Stella, C.; Morschhauser, F.; Bachy, E.; Corradini, P.; Iacoboni, G.; Khan, C.; Patel, K.; Hertzberg, M.; Falchi, L.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Successful brentuximab vedotin and nivolumab therapy of multiply refractory diffuse large B-cell lymphoma with Hodgkin features
    Correspondence

    Zibara, V.; Sen, F.; Scordo, M.; Falchi, L.
    Leukemia and Lymphoma (2022)

    Fulltext@MSK | Save
  • Subcutaneous epcoritamab with rituximab + lenalidomide (R(2)) in patients (pts) with relapsed or refractory (R/R) follicular lymphoma (FL): Update from phase 1/2 trial
    Meeting Abstract

    Falchi, L.; Leppä, S.; Wahlin, B. E.; Nijland, M.; Christensen, J. H.; De Vos, S.; Holte, H.; Linton, K. M.; Abbas, A.; Wang, L.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • First-line treatment (Tx) with subcutaneous (SC) epcoritamab (epco) + R-CHOP in patients (pts) with high-risk diffuse large B-cell lymphoma (DLBCL): Phase 1/2 data update
    Meeting Abstract

    Falchi, L.; Offner, F.; Belada, D.; Brody, J.; Linton, K. M.; Karimi, Y.; Cordoba, R.; Snauwaert, S.; Abbas, A.; Wang, L.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Subcutaneous epcoritamab + R-DHAX/C in patients (pts) with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) eligible for autologous stem cell transplant (ASCT): Preliminary phase 1/2 results
    Meeting Abstract

    Abrisqueta, P.; Falchi, L.; Phillips, T. J.; De Vos, S.; Nijland, M.; Offner, F.; Bykhovski, I.; Wu, J.; Wang, L.; Rana, A.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Subcutaneous epcoritamab combined with R-CHOP for first-line treatment of patients with high-risk diffuse large B-cell lymphoma: Phase 1/2 update
    Meeting Abstract

    Falchi, L.; Offner, F.; Belada, D.; Brody, J.; Linton, K. M.; Karimi, Y.; Cordoba, R.; Snauwaert, S.; Abbas, A.; Wang, L.; more...
    American Journal of Hematology (2022)

    Fulltext@MSK | Save
  • Subcutaneous epcoritamab combined with rituximab + lenalidomide for the treatment of patients with relapsed or refractory follicular lymphoma: Phase 1/2 trial update
    Meeting Abstract

    Falchi, L.; Leppä, S.; Wahlin, B. E.; Nijland, M.; Christensen, J. H.; Vos, S. E.; Holte, H.; Linton, K. M.; Aqeel, A.; Wang, L.; more...
    American Journal of Hematology (2022)

    Fulltext@MSK | Save
  • Adding umbralisib and ublituximab (U2) to ibrutinib in patients with CLL: A phase II study of an MRD-driven approach
    Journal Article

    Roeker, L. E.; Feldman, T. A.; Soumerai, J. D.; Falco, V.; Panton, G.; Dorsey, C.; Zelenetz, A. D.; Falchi, L.; Park, J. H.; Straus, D. J.; more...
    Clinical Cancer Research (2022)

    Fulltext@MSK | Save
  • Activity of AZD7442 (tixagevimab-cilgavimab) against Omicron SARS-CoV-2 in patients with hematologic malignancies
    Research Letter

    Stuver, R.; Shah, G. L.; Korde, N. S.; Roeker, L. E.; Mato, A. R.; Batlevi, C. L.; Chung, D. J.; Doddi, S.; Falchi, L.; Gyurkocza, B.; more...
    Cancer Cell (2022)

    Fulltext@MSK | Save
  • Subcutaneous epcoritamab in combination with rituximab and lenalidomide in relapsed or refractory follicular lymphoma: Preliminary phase 1/2 results
    Meeting Abstract

    Linton, K. M.; Wahlin, B.; Leppä, S.; Morschhauser, F.; Elliott, B.; Liu, T.; Stirner, M. C.; Abbas, A.; Falchi, L.
    British Journal of Haematology (2022)

    Fulltext@MSK | Save